Has the Chinese Clinical Research and Equipment Industry valuation changed over the past few years?

Investors are pessimistic on the Chinese Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 24.2x which is lower than its 3-year average PE of 28.6x. The industry is trading close to its 3-year average PS ratio of 5.0x.

How does Chinese Clinical Research and Equipment compare with similar industries?

There are no additional sub-industries under this industry.

Chinese (SSE) Clinical Research and Equipment Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Thu, 18 Jun 2026	CN¥529.8b	CN¥98.8b	CN¥21.9b	48x	24.2x	5.4x
Sat, 16 May 2026	CN¥584.4b	CN¥98.7b	CN¥21.7b	59.2x	26.9x	5.9x
Mon, 13 Apr 2026	CN¥613.9b	CN¥94.9b	CN¥20.7b	64.5x	29.6x	6.5x
Wed, 11 Mar 2026	CN¥565.7b	CN¥94.5b	CN¥18.7b	61.5x	30.3x	6x
Fri, 06 Feb 2026	CN¥596.7b	CN¥94.4b	CN¥18.6b	63.4x	32.2x	6.3x
Sun, 04 Jan 2026	CN¥547.6b	CN¥94.3b	CN¥18.5b	59.6x	29.6x	5.8x
Tue, 02 Dec 2025	CN¥553.1b	CN¥94.3b	CN¥18.5b	65.2x	29.8x	5.9x
Thu, 30 Oct 2025	CN¥616.2b	CN¥93.8b	CN¥18.9b	68.4x	32.7x	6.6x
Sat, 27 Sep 2025	CN¥604.6b	CN¥92.1b	CN¥17.4b	72.2x	34.7x	6.6x
Mon, 25 Aug 2025	CN¥586.0b	CN¥92.5b	CN¥17.5b	61.4x	33.4x	6.3x
Wed, 23 Jul 2025	CN¥511.2b	CN¥89.8b	CN¥15.4b	52.8x	33.3x	5.7x
Fri, 20 Jun 2025	CN¥414.0b	CN¥89.8b	CN¥15.4b	45.5x	26.9x	4.6x
Sun, 18 May 2025	CN¥392.6b	CN¥89.2b	CN¥15.4b	43.7x	25.5x	4.4x
Tue, 15 Apr 2025	CN¥372.3b	CN¥88.5b	CN¥14.0b	38.6x	26.6x	4.2x
Thu, 13 Mar 2025	CN¥431.5b	CN¥89.0b	CN¥11.3b	44.1x	38.1x	4.9x
Sat, 08 Feb 2025	CN¥386.2b	CN¥88.1b	CN¥11.2b	39.8x	34.3x	4.4x
Mon, 06 Jan 2025	CN¥347.1b	CN¥87.8b	CN¥11.2b	34.2x	31x	4x
Wed, 04 Dec 2024	CN¥376.9b	CN¥87.8b	CN¥11.2b	40.1x	33.7x	4.3x
Fri, 01 Nov 2024	CN¥372.5b	CN¥87.8b	CN¥11.2b	35.7x	33.2x	4.2x
Sun, 29 Sep 2024	CN¥333.6b	CN¥88.2b	CN¥12.4b	31.1x	27x	3.8x
Tue, 27 Aug 2024	CN¥266.1b	CN¥87.4b	CN¥12.3b	24x	21.6x	3x
Thu, 25 Jul 2024	CN¥276.3b	CN¥88.3b	CN¥13.4b	26.3x	20.6x	3.1x
Sat, 22 Jun 2024	CN¥294.0b	CN¥88.3b	CN¥13.4b	25.9x	22x	3.3x
Mon, 20 May 2024	CN¥330.3b	CN¥88.3b	CN¥13.3b	29.1x	24.8x	3.7x
Wed, 17 Apr 2024	CN¥316.6b	CN¥90.3b	CN¥15.0b	29.1x	21.1x	3.5x
Fri, 15 Mar 2024	CN¥373.3b	CN¥90.5b	CN¥15.5b	34.5x	24.1x	4.1x
Sun, 11 Feb 2024	CN¥348.6b	CN¥91.1b	CN¥16.1b	29.9x	21.7x	3.8x
Tue, 09 Jan 2024	CN¥439.7b	CN¥91.1b	CN¥16.1b	36x	27.3x	4.8x
Thu, 07 Dec 2023	CN¥497.9b	CN¥91.1b	CN¥16.1b	36.3x	31x	5.5x
Sat, 04 Nov 2023	CN¥538.0b	CN¥91.0b	CN¥16.1b	38.2x	33.5x	5.9x
Mon, 02 Oct 2023	CN¥520.4b	CN¥92.0b	CN¥18.3b	35.6x	28.4x	5.7x
Wed, 30 Aug 2023	CN¥501.8b	CN¥92.4b	CN¥18.8b	34.7x	26.7x	5.4x
Fri, 28 Jul 2023	CN¥467.8b	CN¥91.3b	CN¥18.5b	33.8x	25.3x	5.1x
Sun, 25 Jun 2023	CN¥454.7b	CN¥91.3b	CN¥18.5b	33.9x	24.6x	5x


CN Market	4.99%
Healthcare	-0.71%
Life Sciences	1.21%
Clinical Research and Equipment	1.21%

Company	Last Price	7D	1Y	Valuation
603259 WuXi AppTec	CN¥102.72	5.8% +CN¥16.8b	58.2%	PE16.2x
603127 Joinn Laboratories(China)Co.Ltd	CN¥35.66	13.6% +CN¥3.1b	87.6%	PE52.8x
688131 Shanghai Haoyuan Chemexpress	CN¥86.37	14.0% +CN¥2.2b	98.6%	PE74.7x
300759 Pharmaron Beijing	CN¥22.71	4.6% +CN¥1.8b	-2.3%	PE24.5x
688114 MGI Tech	CN¥49.90	8.7% +CN¥1.7b	-20.8%	PS7.1x

Announcement • Jun 15

MGI Tech Co., Ltd. Showcases Latest Advancements In Sequencing, Automation And Clinical Genomics At ESHG 2026 Conference

MGI Tech Co., Ltd. showcased its latest advancements in sequencing, automation and clinical genomics at the European Society of Human Genetics (ESHG) 2026 Conference in Gothenburg, Sweden. At Booth 352, MGI welcomed researchers, clinicians, laboratory leaders and industry partners to explore its comprehensive portfolio of sequencing and automation solutions while unveiling new initiatives designed to strengthen collaboration across the genomics ecosystem. A key highlight of ESHG 2026 is the launch of the MGI NGS Partner Enablement Program, a new initiative designed to connect diagnostic developers, assay providers and laboratory partners seeking to build validated clinical workflows on MGI sequencing platforms. The program aims to accelerate the development and adoption of regulated next-generation sequencing (NGS) applications by fostering collaborations that simplify workflow implementation, reduce time-to-market and support broader access to precision medicine solutions. At ESHG 2026, MGI is also announcing new Original Equipment Manufacturer (OEM) partnership opportunities on MGI's DE Bundles (integrated library preparation and sequencing platform), bringing turnkey automation to global partners. The DE Bundle includes the current D4+E25 combination, as well as the new D16 paired with the E25 featuring a new 50M flow cell. The D16, which will be launched later this year, is a benchtop, mid-to-low throughput library prep system and the upgraded successor to the D4. Retaining the fully enclosed contamination control system, it integrates a single-channel robotic pipetting module to maximize automation. With two sample preparation cartridges each processing 8 samples, the D16 delivers significantly higher throughput. The D16 and E25 systems provide flexible and scalable automation solutions for library construction, sequencing, bioinformatics analysis, streamlining the entire laboratory workflow. Through this open OEM framework, MGI is enabling customers and solution providers to integrate proven automation technologies into customized workflows tailored to specific clinical and research applications. MGI hosted its Corporate Satellite Symposium, Advancing Diagnostics: From Clinical Implementation to Biomarker Discovery, bringing together leading experts from across Europe to showcase how advanced genomic technologies are being translated into real-world clinical and research impact. The symposium highlighted applications spanning clinical oncology diagnostics, pharmacogenomics, and spatial multi-omics. Dr. Raquel T. Lima from IPATIMUP (Portugal) presented the clinical value of RNA sequencing for detecting actionable gene fusions in solid tumours, improving diagnostic yield and supporting precision oncology decision-making. Prof. Dr. Andreas Braun from University Hospital Schleswig-Holstein (Germany) shared how spatial biology technologies map the tumour microenvironment in melanoma, revealing tumour heterogeneity, cellular interactions, and mechanisms associated with disease progression and treatment response. Dr. Andrea Conti from BMR Genomics (Italy) explored the opportunities of whole genome sequencing for pharmacogenetic marker evaluation, highlighting how comprehensive genomic approaches can support the implementation of personalised medicine through improved identification of clinically relevant variants. Visitors to the MGI booth can explore the company's comprehensive portfolio of sequencing and automation technologies supporting applications across human genetics, oncology, reproductive health, population genomics and multi-omics research. MGI is showcasing the T7+, its ultra-high-throughput sequencing platform at the conference. Following its official launch for the Europe and Africa region at Analytica 2026 in Munich, the T7+ has gained significant momentum, with 27 units installed worldwide as of the end of 2025. From benchtop to ultra-high-throughput sequencing platforms, as well as advanced laboratory automation solutions, MGI continues to support laboratories seeking high-performance, scalable and cost-effective genomics workflows.

Chinese (SSE) Clinical Research and Equipment Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

Pharmaron Beijing Co., Ltd. Approves Cash Dividend for 2025

MGI Tech Co., Ltd. Showcases Latest Advancements In Sequencing, Automation And Clinical Genomics At ESHG 2026 Conference

603259: Conviction List Addition Will Support Confidence In 2026 Buyback Plan

Dividend increased to CN¥0.13

Investor sentiment deteriorates as stock falls 29%

Now 20% overvalued

Now 20% undervalued after recent price drop

Zhejiang Tailin Bioengineering Co.,Ltd Announces By-Election of Ye Shuming as an Independent Director

Beijing Hotgen Biotech Co., Ltd. (SHSE:688068) announces an Equity Buyback for CNY 100 million worth of its shares.

Now 25% overvalued after recent price rise

First quarter 2026 earnings released: EPS: CN¥0.015 (vs CN¥0.039 in 1Q 2025)

Full year 2025 earnings released: EPS: CN¥1.38 (vs CN¥1.35 in FY 2024)

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2025 earnings released: CN¥1.27 loss per share (vs CN¥2.47 loss in FY 2024)